Table 2.

Tumor responses according to irRECIST.

Cohort A (MSI-H)Cohort B (MSS)
(n = 10)(n = 40)
Best response, n (%)
 CR1 (10.0)0 (0)
 PR4 (40.0)4 (10.0)
 SD4 (40.0)14 (35.0)
 Disease progression1 (10.0)21 (52.5)
 Not evaluated0 (0)1 (2.5)
ORR, % (95% CI)50.0 (18.7–81.3)10.0 (2.8–23.7)
DCR, % (95% CI)90.0 (55.5–99.7)45.0 (29.3–61.5)
DOR, months, median (95% CI)NR (7.9–NR)9.0 (1.7–9.0)